Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population

Cancer Biomarkers

Volumn 12, Issue 4-5, 2012, Pages 177-184

  Joseph, Sasha ^a   Harrington, Ryan ^a   Walter, Dawn ^a   Goldberg, Judith D ^a   Li, Xiaochun ^a   Beck, Amanda ^a   Litton, Tyler ^a   Hirsch, Nathalie ^a   Blasberg, Justin ^b   Slomiany, Mark ^a   Rom, William ^a   Pass, Harvey ^a   Donington, Jessica ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarker; CT screening; early detection; Non small cell lung cancer; osteopontin

Indexed keywords

OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER SCREENING; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG NON SMALL CELL CANCER; MEASUREMENT ACCURACY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SMOKING;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OSTEOPONTIN; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84876253833     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130306     Document Type: Article

References (27)

1. Jemal, A., et al.., Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): 277-300.
2. Aberle, D.R., et al.., Reduced lung-cancer mortality with lowdose computed tomographic screening. The New England journal of medicine, 2011. 365(5): 395-409.
3. Henschke, C.I., CT screening for lung cancer: update 2005. Surg Oncol Clin N Am. 2005 Oct; 14(4): 761-76.
4. Henschke, C.I., et al.., Survival of patients with stage I lung cancer detected on CT screening. The New England journal of medicine, 2006. 355(17): 1763-71. (Pubitemid 44631359)
5. Gohagan, J., et al.., Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: The Lung Screening Study of the National Cancer Institute. Chest, 2004. 126(1): 114-21. (Pubitemid 38943126)
6. Sone, S., et al.., Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet, 1998. 351(9111): 1242-5. (Pubitemid 28181964)
7. Diederich, S., et al.., Screening for early lung cancer with lowdose spiral CT: prevalence in 817 asymptomatic smokers. Radiology, 2002. 222(3): 773-81. (Pubitemid 34215229)
8. Senger, D.R., D.F.Wirth, and R.O. Hynes, Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 1979. 16(4): 885-93. (Pubitemid 9161338)
9. O'Regan, A., The role of osteopontin in lung disease. Cytokine Growth Factor Rev, 2003. 14(6): 479-88. (Pubitemid 37296021)
10. Bellahcene, A., et al.., Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer, 2008. 8(3): 212-26. (Pubitemid 351301854)
11. Ashkar, S., et al.., Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000. 287(5454): 860-4. (Pubitemid 30084330)
12. Liaw, L., et al.., Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest, 1998. 101(7): 1468-78. (Pubitemid 28166845)
13. Blasberg, J.D., et al.., Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol, 2010. 28(6): 936-41.
14. Le, Q.T., et al.., An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res, 2006. 12(5): 1507-14.
15. Mack, P.C., et al.., Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol, 2008. 26(29): 4771-6.
16. Chambers, A.F., et al.., Osteopontin expression in lung cancer. Lung Cancer, 1996. 15(3): 311-23. (Pubitemid 26399511)
17. Greenberg, A.K., et al.., CT Scan Screening for Lung Cancer: Risk Factors for Nodules and Malignancy in a High-Risk Urban Cohort. PLoS One, 2012. 7(7): e39403.
18. Carter, H.B., et al.., Longitudinal evaluation of prostatespecific antigen levels in men with and without prostate disease. JAMA : the journal of the American Medical Association, 1992. 267(16): 2215-20.
19. Yu, X., et al.., Comparison of methods for calculating prostate specific antigen velocity. The Journal of urology, 2006. 176(6 Pt 1): 2427-31; discussion 2431. (Pubitemid 44755070)
20. Pahikkala, T., et al.., Exact and efficient Leave-pair-out Crossvalidation for ranking RLS. Proceedings of the 2nd International and Interdisciplinary Conference on Adaptive Knowledge Representation and Reasoning (AKRR'08), 2008, 1-8.
21. Pinheiro, J., et al.., Mixed Effects Models in S and S-PLUS. 2009, Springer.
22. Zweig, M.H. and G. Campbell, Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem, 1993. 39(4): 561-77. (Pubitemid 23118304)
23. Hanley, J.A. and B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982. 143(1): 29-36. (Pubitemid 12142173)
24. Schroder, F.H., et al.., Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 2009. 360(13): 1320-8.
25. Lorenzen, J.M., et al.., Osteopontin in patients with idiopathic pulmonary hypertension. Chest, 2011. 139(5): 1010-7.
26. Hu, Z., et al.., Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res, 2005. 11(13): 4646-52. (Pubitemid 41557181)
27. MacMahon, H., et al.., Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology, 2005. 237(2): 395-400. (Pubitemid 41507873)